Longeveron

Contributing Author

Recent Articles by Longeveron

Mar-17	Longeveron Announces 2025 Full Year Financial Results and Provides Business Update LGVN +8.14% GlobeNewswire
Mar-12	Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 LGVN GlobeNewswire
Mar-11	Longeveron Announces Closing of Private Placement of up to $30 Million LGVN -8.81% GlobeNewswire
Mar-10	Longeveron Announces Private Placement of up to $30 Million LGVN +68.27% GlobeNewswire
Feb-25	Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell LGVN +5.72% LGVN -5.63% GlobeNewswire
Feb-13	Longeveron Appoints Stephen H. Willard as Chief Executive Officer LGVN GlobeNewswire
Feb-05	Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program LGVN -5.34% GlobeNewswire
Jan-29	Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) LGVN GlobeNewswire
Jan-26	Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) LGVN +6.17% GlobeNewswire
Dec-29	Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 LGVN GlobeNewswire
Dec-17	Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy LGVN +7.81% GlobeNewswire
Dec-03	Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum LGVN GlobeNewswire
Dec-02	Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging LGVN GlobeNewswire
Dec-01	Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) LGVN -5.08% GlobeNewswire
Nov-19	Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) LGVN GlobeNewswire
Nov-12	Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy LGVN GlobeNewswire
Nov-04	Longeveron Announces Third Quarter 2025 Financial Results and Provides Business Update LGVN GlobeNewswire
Oct-28	Longeveron to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 LGVN GlobeNewswire
Oct-27	Longeveron Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect LGVN GlobeNewswire
Oct-06	Longeveron to Participate in the 4th Annual ROTH Healthcare Opportunities Conference LGVN GlobeNewswire
Oct-01	George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron Board of Directors LGVN GlobeNewswire
Sep-22	Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa LGVN GlobeNewswire
Sep-03	Longeveron Announces Key Leadership Updates LGVN -8.31% LGVN GlobeNewswire
Aug-20	Longeveron to Present at the H.C. Wainwright 27th Annual Global Investment Conference LGVN GlobeNewswire
Aug-13	Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update LGVN +26.38% LGVN -12.19% GlobeNewswire
Aug-11	Longeveron Announces Closing Of Up To $17.5 Million Public Offering LGVN GlobeNewswire
Aug-08	Longeveron Announces Up To $17.5 Million Public Offering LGVN -46.62% GlobeNewswire
Aug-05	Longeveron to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 LGVN -9.36% GlobeNewswire
Jul-21	Longeveron Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease LGVN +10.53% GlobeNewswire
Jul-08	Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) LGVN +28.68% GlobeNewswire
Jun-26	Longeveron Appoints Than Powell as Chief Business Officer LGVN GlobeNewswire
Jun-24	Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) LGVN +7.83% GlobeNewswire
Jun-09	Longeveron to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference LGVN GlobeNewswire
May-20	Longeveron to Attend BIO International Convention 2025 LGVN GlobeNewswire
May-12	Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient LGVN +9.70% GlobeNewswire
May-08	Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update LGVN -10.07% LGVN GlobeNewswire
May-02	Longeveron to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 LGVN GlobeNewswire

Longeveron

Recent Articles by Longeveron

Upgrade your FINVIZ experience